Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. User Boards ›
  4. NASDAQ OMX GlobeNewswire Message Board

Tabula Rasa HealthCare and Landmark to Improve Pat

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 301275
(Total Views: 56)
Posted On: 05/01/2017 8:00:22 PM
Avatar
Posted By: News Desk 2018
Tabula Rasa HealthCare and Landmark to Improve Patient Outcomes in California and New York  

MOORESTOWN, N.J. and HUNTINGTON BEACH, Calif., May 01, 2017 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare , Inc. (NASDAQ: TRHC ), a healthcare technology company disrupting the field of medication safety, has licensed the use of its medication risk mitigation platform, MedWise Advisor® , to Landmark, a leading national medical group focused exclusively on the most chronically ill patients.

TRHC Chairman and CEO, Calvin H. Knowlton, PhD, commented, “We look forward to this new partnership with Landmark. This marks the first time Tabula Rasa will license the use of its platform for other clinicians to use in improving therapeutic outcomes. The new application of our solution further proves the flexibility of MedWise Advisor®, and provides a model to address the demand in our pipeline.

This partnership will allow us to expand our services to new and broader markets where we will not only be able to counteract one of the most avoidable causes of death and unintended medical injuries, but also continue to deliver on our goal of improving patient outcomes and lowering costs by reducing the occurrence of adverse drug events.”

Landmark is teaming up with Tabula Rasa to deploy the MedWise Advisor® platform, allowing Landmark clinicians to identify opportunities to improve the safety of their members’ medication profiles. Tabula Rasa’s pharmacist-staffed call centers also will provide “as-needed” clinical support to Landmark’s clinicians. First phase of the program will be launched by Landmark in two of its markets, California and New York.

“Tabula Rasa’s mission clearly aligns with ours,” said Landmark’s Chief Medical Officer, Dr. Michael Le. “Our patients are often on many different medications with the potential for complex interactions and unintended risk. Our Phase One engagement with Tabula Rasa will allow us to proactively identify patients with elevated risk profiles, and more importantly, enable our clinical staff to intervene and improve the patient’s medication regimen before any incident occurs.”

Dr. Le continued, “The ultimate goal of our collaboration is to use Tabula Rasa’s medication decision support tools to help reduce unnecessary hospitalizations and visits to the emergency room within our population, and to keep our patients healthier, with improved quality of life, at home.”

About Landmark Landmark is helping people age in place, with quality and dignity in their home. Their community-based, physician-led clinical teams are specialized in house calls and deliver medical, behavioral, social and palliative care to individuals with multiple chronic conditions, when and where it’s needed – 24 hours a day, 7 days a week. Their team of mobile clinicians collaborate with patients’ families, caregivers and other medical providers to bring coordinated world-class healthcare to people of any class. Learn more at LandmarkHealth.org.

About Tabula Rasa HealthCare Tabula Rasa HealthCare (NASDAQ: TRHC ) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk.  Medication risk management is TRHC’s lead offering, and its cloud-based software applications provide solutions for a range of payers, providers and other healthcare organizations. For more information, please visit: www.trhc.com .

Contact:                                                                                                                               Media Dianne Semingson dsemingson@TRHC.com T: 215-870-0829 Investors Bob East or Asher Dewhurst Westwicke Partners 443-213-0500 tabularasa@westwicke.com



(0)
(0)








Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us